Putative rhesus macaque germline predecessors of human broadly HIV-neutralizing antibodies: Differences from the human counterparts and implications for HIV-1 vaccine development

Vaccine

Volumn 29, Issue 40, 2011, Pages 6903-6910

  Yuan, Tingting ^a   Li, Jingjing ^a   Zhang, Yu ^a   Wang, Yanping ^b   Streaker, Emily ^b   Dimitrov, Dimiter S ^b   Zhang, Mei Yun ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

B cell repertoire; HIV AIDS; Neutralizing antibodies; Rhesus macaque; Somatic maturation; Vaccine

Indexed keywords

ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE SEQUENCE; GERM LINE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MACACA; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; CELL LINE, TRANSFORMED; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GERM-LINE MUTATION; HEK293 CELLS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; MACACA MULATTA;

EID: 80052314665     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.046     Document Type: Article

References (26)

1. Kwong P.D., Wyatt R., Majeed S., Robinson J., Sweet R.W., Sodroski J., et al. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure 2000, 8(December (12)):1329-1339.
2. Kwong P.D., Doyle M.L., Casper D.J., Cicala C., Leavitt S.A., Majeed S., et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002, 420(December (6916)):678-682.
3. Chen L., Kwon Y.D., Zhou T., Wu X., O'Dell S., Cavacini L., et al. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 2009, 326(November (5956)):1123-1127.
4. Xiao X., Chen W., Feng Y., Zhu Z., Prabakaran P., Wang Y., et al. Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem Biophys Res Commun 2009, 390(September (3)):404-409.
5. Xiao X., Chen W., Feng Y., Dimitrov D.S. Maturation pathways of cross-reactive HIV-1 neutralizing antibodies. Viruses 2009, I:801-817.
6. Wu X., Yang Z.Y., Li Y., Hogerkorp C.M., Schief W.R., Seaman M.S., et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV. Science 2010, 329(July (5993)):856-861.
7. Pancera M., McLellan J.S., Wu X., Zhu J., Changela A., Schmidt S.D., et al. Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J Virol 2010, 84(August (16)):8098-8110.
8. Barnett S.W., Srivastava I.K., Kan E., Zhou F., Goodsell A., Cristillo A.D., et al. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS 2008, 22(January (3)):339-348.
9. Cristillo A.D., Wang S., Caskey M.S., Unangst T., Hocker L., He L., et al. Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine. Virology 2006, 346(March (1)):151-168.
10. Derby N.R., Kraft Z., Kan E., Crooks E.T., Barnett S.W., Srivastava I.K., et al. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection. J Virol 2006, 80(September (17)):8745-8762.
11. Gupta S., Zhou F., Greer C.E., Legg H., Tang T., Luciw P., et al. Antibody responses against HIV in rhesus macaques following combinations of mucosal and systemic immunizations with chimeric alphavirus-based replicon particles. AIDS Res Hum Retroviruses 2006, 22(October (10)):993-997.
12. Kraft Z., Derby N.R., McCaffrey R.A., Niec R., Blay W.M., Haigwood N.L., et al. Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies. J Virol 2007, 81(June (12)):6402-6411.
13. Watkins D.I., Burton D.R., Kallas E.G., Moore J.P., Koff W.C. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med 2008, 14(June (6)):617-621.
14. Burton D.R., Pyati J., Koduri R., Sharp S.J., Thornton G.B., Parren P.W., et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994, 266(November (5187)):1024-1027.
15. Zhou T., Xu L., Dey B., Hessell A.J., Van Ryk D., Xiang S.H., et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007, 445(February (7129)):732-737.
16. Zhang M.Y., Shu Y., Phogat S., Xiao X., Cham F., Bouma P., et al. Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library. J Immunol Methods 2003, 283(December (1-2)):17-25.
17. Helmuth E.F., Letvin N.L., Margolin D.H. Germline repertoire of the immunoglobulin V(H)3 family in rhesus monkeys. Immunogenetics 2000, 51(June (7)):519-527.
18. Bible J.M., Howard W., Robbins H., Dunn-Walters D.K. IGHV1, IGHV5 and IGHV7 subgroup genes in the rhesus macaque. Immunogenetics 2003, 54(March (12)):867-873.
19. Andris J.S., Miller A.B., Abraham S.R., Cunningham S., Roubinet F., Blancher A., et al. Variable region gene segment utilization in rhesus monkey hybridomas producing human red blood cell-specific antibodies: predominance of the VH4 family but not VH4-21 (V4-34). Mol Immunol 1997, 34(February (3)):237-253.
20. Barbas C.F., Burton D.R., Scott J.K., Silverman G.J. Phage display a laboratory manual 2001, Cold Spring Harbor Laboratory Press, Cold Spring Harbor.
21. Zhang M.Y., Shu Y., Rudolph D., Prabakaran P., Labrijn A.F., Zwick M.B., et al. Improved breadth and potency of an HIV-1-neutralizing human single-chain antibody by random mutagenesis and sequential antigen panning. J Mol Biol 2004, 335(January (1)):209-219.
22. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005, 79(August (16)):10108-10125.
23. Link J.M., Larson J.E., Schroeder H.W. Despite extensive similarity in germline DH and JH sequence, the adult Rhesus macaque CDR-H3 repertoire differs from human. Mol Immunol 2005, 42(May (8)):943-955.
24. Wu-Baer F., Sigman D., Gaynor R.B. Specific binding of RNA polymerase II to the human immunodeficiency virus trans-activating region RNA is regulated by cellular cofactors and Tat. Proc Natl Acad Sci U S A 1995, 92(August (16)):7153-7157.
25. Yuan T., Li J., Zhang M.Y. A single mutation turns a non-binding germline-like predecessor of broadly neutralizing antibody into a binding antibody to HIV-1 envelope glycoproteins. MAbs 2011, 3(July (4)).
26. Zhou T., Georgiev I., Wu X., Yang Z.Y., Dai K., Finzi A., et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010, 329(July (5993)):811-817.